Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, breast cancer
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan (Dato-DXd) is a new form of cancer treatment,
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
Key Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
15h
on MSN
AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges
We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...
MM&M
3d
AstraZeneca’s ‘What science can do’ campaign highlights company’s scientific achievements
In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.
FierceBiotech
4d
AstraZeneca extends AI immuno-oncology R&D pact with Immunai
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...
17h
on MSN
Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?
We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where AstraZeneca PLC (NASDAQ ...
5h
Fiem Industries Or AstraZeneca Pharma: 2 Technical Picks By Sumeet Bagadia On Tuesday, 1st October
On Tuesday, October 1st, Choice Broking executive director Sumeet Bagadia recommended buying two stocks, emphasising the ...
4d
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
6d
AstraZeneca: Buy This Big Pharma Stock At A Discount Now
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
中国日报网
1d
AstraZeneca announces plans for new innovations for China
United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...
MarketWatch on MSN
6d
AstraZeneca falls Tuesday, underperforms market
Shares of AstraZeneca PLC AZN inched down 0.54% to £115.22 Tuesday, on what proved to be an all-around positive trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
China
India
Trade
Artificial intelligence
United States
Feedback